In the full cohort (n = 22) excluding relapsed DLBCL-NOS, no significant associations were found between 5-year survival rates and MYD88 pathogenic variants, COO, or double-expressor lymphoma (Table 2). The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.